Cantor Stays Positive on Jazz Pharmaceuticals (JAZZ), Sees Purchase of PRV As Potentially Useful Tool for Asset Development
Tweet Send to a Friend
Cantor Fitzgerald maintains Overweight on Jazz Pharmaceuticals (NASDAQ: JAZZ) price target of $202.00.Analyst William Tanner comments "We believe the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
